6 completed, 3 terminated, 1 withdrawn. 6 Phase 2, 3 Phase 1, 1 Phase 3.
By phase and status
Follow farletuzumab: new trials by email Literature Review of farletuzumab trials Research Report on farletuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer
Farletuzumab, Placebo - Platinum-Sensitive Ovarian Cancer in First Relapse | Phase 2 | Completed | Eisai Inc. | 332 | 2015-03-19 | 2021-09-02 |
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Farletuzumab, Placebo, Carboplatin - Adenocarcinoma of the Lung | Phase 2 | Completed | Morphotek | 130 | 2011-06-27 | 2020-08-20 |
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Farletuzumab - Resectable, Non-functioning Pituitary Adenoma | Phase 2 | Withdrawn | Morphotek | | 2011-02-01 | 2013-11-04 |
An Open Label Extension Study of the Efficacy of MORAb-003
MORAb-003 - Epithelial Ovarian Cancer | Phase 2 | Terminated | Morphotek | 3 | 2010-01-13 | 2021-12-08 |
A Study of MORAb-003 in Patients With Solid Tumor
MORAb-003 - Neoplasms, Solid Tumor | Phase 1 | Completed | Eisai Co., Ltd. | 16 | 2010-01-01 | 2020-06-11 |
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Farletuzumab, Carboplatin, and PLD - Epithelial Ovarian Cancer | Phase 1 | Completed | Morphotek | 15 | 2009-11-01 | 2014-07-17 |
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Farletuzumab, Carboplatin, Taxane - Ovarian Cancer | Phase 3 | Terminated | Morphotek | 1100 | 2009-04-16 | 2022-12-30 |
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel - Ovarian Cancer | Phase 2 | Terminated | Morphotek | 415 | 2008-09-01 | 2017-03-30 |
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Farletuzumab, Chemo Plus Far - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Morphotek | 58 | 2006-05-01 | 2015-09-09 |
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
MORAb-003 - Epithelial Ovarian Cancer | Phase 1 | Completed | Morphotek | 24 | 2005-06-01 | 2013-11-06 |
Conditions studied
Ovarian Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Adenocarcinoma of Lung (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1) · Peritoneal Neoplasms (1) · Pituitary Neoplasms (1)
Sponsors
Morphotek (8) · Eisai Co., Ltd. (1) · Eisai Inc. (1)
Countries
United States (9) · Germany (5) · Spain (4) · Australia (3) · Belgium (3) · Canada (3) · Italy (3) · Japan (3) · Netherlands (2) · Poland (2) · Russia (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1)
Top investigators
Susan Weil, MD (2) · Bruce Wallin, MD (1) · Chifumi Kitamura (1) · Jason Konner, M.D. (1) · Nelson Oyesiku, MD, PhD, FACS (1) · Susan C. Weil, M.D. (1)
Results publications
PMID 23474348, PMID 25380636, PMID 36758420
NIH funding
2008 (1), 2009 (1)